Key facts
- Notable investors include iAccel (Seongnam-si).
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for NEUROLYNX
- ·The full record, as it builds
Funding rounds
No funding rounds for NEUROLYNX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NEUROLYNX
Developer of microphysiological neural modeling systems designed for neurological research purposes. The company's platform integrates human cell-based brain tissue models, blood-brain barrier simulation, automated drug testing environments, imaging tools, and analytical software for evaluating compound penetration, neuronal responses, and disease-related cellular interactions in controlled laboratory conditions, enabling pharmaceutical and biotechnology research organizations to conduct experimental studies on neurological disorders and assess potential therapeutic compounds.
- Sector
- Healthcare
- HQ
- Suwon, South Korea
- Website
- neuro-lynx.com/
- Ownership
- Privately Held (backing)
NEUROLYNX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NEUROLYNX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NEUROLYNX in its N-PORT filings yet. We sweep new filings monthly.